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Volume 57, Number 1 Abstracts 289ultrasound imaging at 1 year, 10 patients have no follow-up data (three of
whom surgery was recently completed, seven of which were lost to follow-
up), and eight patients experienced thrombosis. Stents extended into the
inferior vena cava crossing the normal contralateral side in 45 of 66 patients
(68%). Seven of these patients (15%) suffered new thrombosis of the
nonstented contralateral side. Three of these seven patients were totally
noncompliant with their postoperative anticoagulation; thus, 8% of compli-
ant patients had new contralateral thrombosis after stenting across a normal
contralateral common iliac vein and into the vena caval wall.
Conclusions: To date, there is no consensus whether to stent across
the thrombosed common iliac vein into the cava or completely across and
into the vena cava. From these data it appears that stenting across the
iliocaval confluence can result in a small percentage of contralateral throm-
bosis despite chronic therapeutic anticoagulation. This data will help us
move forward in the development of new technologies and in the treatment
of these patients.
Surgical Reconstruction of the Cephalic Arch for the Management of
Dysfunctional Brachiocephalic Arteriovenous Fistulas
Javier E. Anaya-Ayala, MD, Nader Zamani, BS, Nyla Ismail, PhD, Tony Lu,
MD, Cassidy Duran, MD, Hosam F. El-Sayed, MD, Mark G. Davies, MD,
PhD, MBA, Eric K. Peden, MD. Methodist DeBakey Heart & Vascular
Center, Houston, Tex
Objectives:Development of recalcitrant stenotic lesions of the cephalic
arch is a common failure mode of brachiocephalic arteriovenous fistulas.
Endovascular treatment is the first line of therapy for cephalic arch stenosis.
Suboptimal outcomes have led to exploration of surgical alternatives. We
evaluated our initial experience with a cephalic arch reconstruction to salvage
malfunctioning brachiocephalic arteriovenous fistulas (AVFs).
Methods: We retrospectively reviewed all patients requiring surgical
revision of compromised brachiocephalic AVFs due to cephalic arch stenosis.
Percutaneous interventions had failed in all patients, and they underwent
cephalic arch reconstruction (CAR) for salvage. Indications, clinical consid-
erations, and surgical technique were studied; initial patency, complications
and reinterventions were reviewed.
Results: From April 2011 to July 2012, 15 patients (54% women, mean
age 55 22 years) underwent CAR. Stenotic lesions of the cephalic arch at the
confluence with the axillary vein were confirmed by contrast venography. The
average number of percutaneous interventions prior to the decision toCARwas
three (range, 2-7).The time fromaccess creation to cephalic arch reconstruction
was 33 months. Surgical approach involved revisions of the cephalic arch to
redirect the flow as a direct reconnection to the axillary or as a turndown
procedure to the brachial vein in the axilla. Technical success was 100%: all
patients were able to use successfully their access for dialysis after the procedure.
Two patients (13%) required angioplasty of the CAR due to restenosis, another
patient required evacuation of hematoma in postoperative day 14. At a mean of
12 months of follow-up, all AVFs remain functional.
Conclusions: The initial experience with cephalic arch reconstruction
demonstrates that is an effective surgical option to salvage brachiocephalic
AVFs with excellent short-term and functional results (Fig).
Transarterial Treatment of Congenital Renal Arteriovenous Fistulas
Naiem Nassiri, MD, Hirra Ali, MD, Alfio Carroccio, MD, Robert J. Rosen,
MD. Lenox Hill Heart & Vascular Institute of New York, New York, NY
Objectives: Congenital renal arteriovenous fistulas (CRAVFs) repre-
sent a distinct and often misdiagnosed clinical entity with characteristic
hemodynamic and angiographic features. Treatment is warranted given
potential for growth with renal and hemodynamic compromise. We report
our experience with a series of treated symptomatic CRAVFs.
Fig.Methods: During a 10-year period, patients treated for symptomatic
CRAVFs (no history of predisposing renal pathology, instrumentation,
a
eeoplasm, or trauma) were retrospectively investigated for clinical presenta-
ion, radiographic features, treatment outcomes, and complications. A tech-
ically successful treatment included successful delivery of an embolic agent
ith complete obliteration of the fistula. Clinical success included resolution
f symptoms and freedom from recurrence and reintervention. Renal paren-
hymal loss as demonstrated by postembolization angiography was catego-
ized as 0%, 25%, 25% to 50%, or 50%.
Results: Twenty-five patients (8 women) were referred with a pre-
umptive diagnosis of intraparenchymal renal artery aneurysm. Of these, 10
ad true intrarenal aneurysms, three had angiomyolipomas, and 12 had
RAVFs (mean age, 54 years; range 29-71 years). Presenting symptoms
ncluded gross hematuria (n  8), refractory hypertension (diastolic blood
ressure 90 mm Hg despite 3 medications; n  6), flank pain (n  8),
igh-output state (featuring tachycardia and jugular venous distention; n 
), and flank bruit (n  1). Defining angiographic features included a
igh-flow arteriovenous fistula fed by a single, enlarged intrarenal branch
hunting into a dilated vein, occasionally featuring a calcified rim (n 4). All
atients underwent transarterial embolization with coils (n  5), coils and
-butylcyanoacrylate (n  3), detachable balloons (n  2), or Amplatzer
lugs (n 2). Technical success was 100%. Hematuria, tachycardia, jugular
enous distention, pain, and bruit resolved in all. Hypertension improved in
our of six patients (required one medication after embolization). Compli-
ations included a transient, self-limited postprocedural flank discomfort in
ine patients. Parenchymal loss was limited to 25% and occurred in five
atients. There were no recurrences or reinterventions at a mean follow-up
f 55 months (range, 5-96 months). There was one death at 8 years’
ollow-up from intercurrent coronary disease in a patient without high-
utput state.
Conclusions: CRAVF is a rare and likely underdiagnosed clinical
ntity. With greater awareness and accurate diagnosis, effective and durable
ransarterial treatment can be safely performed (Fig).
actors Associated With Primary Vein Graft Thrombosis in a Multi-
enter Trial With Mandated Ultrasound Surveillance
awrence B. Oresanya, MD,1 Gregory L. Moneta, MD,2 Michael Belkin,
D,3 Michael S. Conte, MD1. 1University of California San Francisco, San
rancisco, Calif; 2Oregon Health and Science University, Portland, Ore;
Brigham and Women’s Hospital, Boston, Mass
Objectives: The benefits of preventing lower extremity vein bypass
raft (LEVBG) occlusion through duplex ultrasound (DUS) surveillance
nd timely reintervention are established. However, even in the setting of
urveillance, a significant number of LEVBG become occluded as a first
vent. We sought to identify factors that may contribute to these primary
cclusions using a multicenter clinical trial database.
Methods: This was a retrospective analysis of the PREVENT III
ohort of 1404 patients with critical limb ischemia who underwent LEVBG.
articipants were followed up with DUS at regular intervals (1, 3, 6, 9, and
2 months), with reintervention based on prespecified DUS criteria. Pa-
ients who had graft occlusion as the initial graft-related event were identi-
ed, and technical failures (adjudicated) were excluded.Multivariate analysis
as used to identify predictors of primary graft occlusion.
Results: Primary graft occlusion occurred in 200 participants (14%),
Fig.ccounting for 34% of all initial graft-related events. Primary occlusion
vents were distributed throughout the postoperative year. Rates of recur-
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January 2013290 Abstractsrent critical limb ischemia, loss of secondary patency, and major amputation
in those with primary occlusion were 55%, 79%, and 22%, respectively,
compared with 18%, 10%, and 10% for the remaining cohort (P .001). On
univariate analysis (hazard ratio [HR] [95% confidence interval]), African
American race (1.4 [1.01-1.9]), use of anticoagulants (1.54 [1.2-2]), use of
alternative/spliced vein conduit (1.44 [1.1-1.97]) and graft diameter 3
mm (1.97 [1.2-3.3]) were associated with increased risk of primary occlu-
sion. Onmultivariate analysis (HR [95% confidence interval]) graft diameter
3 mm (1.8 [1.1-3]) and use of anticoagulants (1.4 [1.04-1.89]) were
independent predictors. In 110 individuals, DUS had revealed no critical
threshold abnormalities prior to the thrombosis. On multivariate analysis,
graft diameter3mm (2.3 [1.2-4.7]) was the sole independent predictor of
these unheralded occlusions.
Conclusions: Approximately one-third of primary vein graft events are
occlusions even in the setting of DUS surveillance. Smaller diameter grafts
are at increased risk. These findings suggest that prevention of vein graft
thrombosis requires further improvements in risk stratification, surveillance,
and antithrombotic therapies.
Outcomes of Percutaneous Lower Extremity Procedures DependMore
on Indication Than Physician Specialty
Justin R. Wallace, MD, Theodore H. Yuo, MD, Rabih A. Chaer, MD,
Michel S. Makaroun, MD. UPMC, Pittsburgh, Pa
Objectives: Outcomes of percutaneous lower extremity procedures
(PLEP) have been recently linked to physician specialty. Unfortunately, the
indication for intervention was not reported. We sought to compare out-
comes between specialties performing PLEP for different indications in a
recent statewide inpatient discharge data set.
Methods: The Florida hospital discharge data from 2005 to 2009 was
reviewed for patients with PLEP during hospitalization. We assigned physi-
cian specialty as interventional radiology (IR), interventional cardiology
(IC), or vascular surgery (VS) based on physician-associated procedures.
Clinical indication was claudication or critical limb ischemia (CLI). We
limited our analysis to patients without concomitant open surgery during
hospitalization. We compared mortality, length of stay (LOS), major use of
intensive care unit (ICU), discharge disposition, and total charges between
specialties with logistic regression models, both unadjusted and adjusted for
demographic and clinical characteristics.
Results: A total of 15,398 patients (47% with CLI) had a PLEP. IC
performed the majority of procedures on claudicant patients (VS 30%, IC
57%, IR 13%), and VS performed themajority of procedures on CLI patients
(VS 50%, IC 22%, IR 27%). VS and IR were more likely than IC to treat CLI
patients (VS 59%, IR 65%, IC 26%; P  .001). Among CLI patients, there
was no difference in mortality rates between the three specialties in unad-
justed analysis (VS 2.3%, IR 3.0%, IC 2.1%, P .124), nor after adjustment
(odds ratio [OR] VS, reference; IR, 1.05; IC, 0.82; P  NS for both).
However, compared with VS, IR-treated patients were less likely to be
discharged home (OR, 0.73; P .001), LOS was longer (, 1.15 days; P
.001), major ICU use was more common (OR, 1.48; P  .001), and total
charges were higher (, $3267; P  .001). CLI was most predictive for
death (OR, 4.02; P .001), major ICUuse (OR, 1.95; P .001), discharge
home (OR, 0.50; P  .001), increased LOS (, 3.25 days; P  .001), and
total charges (, $18,364; P  .001).
Conclusions: VS treat the majority of CLI patients, while IC treat
mostly claudicant patients. Although physician specialty does impact several
clinical outcomes, the clinical indication for PLEP is the strongest predictor
of adverse outcomes. Future outcome analyses of PLEP should adjust for
clinical indication.
The Growing Burden of Restenosis in Peripheral Arterial Disease and
Its Impact on Outcomes
Douglas W. Jones, MD,1 Andres Schanzer, MD,2 Yuanyuan Zhao, MS,3
Michael S. Conte, MD,4 Philip P. Goodney, MD, MS3. 1New York
Presbyterian Hospital–Weill-Cornell Medical Center, New York, NY; 2Uni-
versity of Massachusetts Medical School, Worcester, Mass; 3Dartmouth
Hitchcock Medical Center, Lebanon, NH; 4University of California, San
Francisco, San Francisco, Calif
Objectives: Primary peripheral vascular interventions (PVI) and surgi-
cal bypass often suffer from restenosis, and secondary procedures performed
following restenosis may have poorer outcomes. We investigated how com-
monly lower extremity bypass (LEB) is performed in the setting of a prior
PVI or surgical bypass (“secondary LEB”), and how the outcomes of
secondary LEB compare to primary LEB.
Methods: Within the Vascular Surgery Group of New England
(VSGNE), we studied 3,504 patients who underwent LEB (2003-2011).
We compared utilization, indications, and outcomes between patients who
had primary versus secondary LEB. In-hospital outcomes and outcomes at
1-year follow-up were analyzed and inverse propensity weighting was per-
formed to adjust for differences between the two groups. Subgroup analyses
were performed to determine the influence of indication (claudication/
i
1ritical limb ischemia [CLI]) and prior intervention type (PVI/LEB/both)
n outcomes for secondary LEB.
Results: Overall, we studied 2350 patients undergoing primary LEB,
nd 1154 secondary LEB patients who underwent LEB in the setting of a
rior PVI (48%), a prior bypass (37%), or both (14%). Of all patients who
nderwent LEB, the proportion of patients undergoing secondary LEB has
oubled over the last 9 years (22% in 2003, 38% in 2011; P  .001). This
ncrease was evident in treatment of patients with CLI (18% to 28% of all
EB; P .001) and claudication (4% to 10% of all LEB; P .001) (Fig). In
rude analyses, rates of in-hospital myocardial infarction (4%), death (2%), or
mputation (0.5%) were similar between patients undergoing primary and
econdary LEB. However, secondary LEB patients had significantly worse
verall freedom from death, reintervention or above-ankle amputation
RAO; 58.9% vs 64.1%; P .001), and worse freedom from death or major
dverse limb event (MALE; 61.6% vs 67.5%; P 0.001) at 1-year follow-up.
hese results persisted, even when using inverse propensity weighting to
ccount for differences in patients characteristics. On subgroup analysis,
nferior RAO-free survival and MALE-free survival in patients undergoing
econdary LEB was independent of the type of prior revascularization (PVI,
EB, or both).
Conclusions: The proportion of patients who undergo LEB as a
econdary procedure has increased significantly in recent years in patients
ith both claudication and CLI and their associated outcomes are worse. In
n era where many advocate an endovascular-first approach to all patients
ith lower extremity PAD, physicians should consider the first intervention
arefully, not only because of the potential immediate implications, but also
ecause of the implications of treatment failure on future events.
ospital Reimbursement for Carotid Stenting and Carotid
ndarterectomy
elissa J. Donovan, MD, Daniel E. Ramirez, MD, Gregory D. Crenshaw,
D, Taylor A. Smith, MD, Hernan A. Bazan, MD, W. Charles Sternbergh,
II, MD. Ochsner Medical Center, New Orleans, La
Objectives: We previously demonstrated that carotid artery stenting
CAS) had a 40% greater cost than carotid endarterectomy (CEA) and did
ot provide superior outcome or a reduction in length of stay. However,
edicare hospital reimbursement for CAS (DRGs 34, 35, 36) is 12% to 61%
reater than that for CEA (DRGs 37, 38, 39). Hospital reimbursement for
hese procedures has not been previously examined.
Methods: A retrospective review of the hospital reimbursement and
ost for CAS and CEA was performed over a 33-month period at a tertiary
are institution. This financial data was calculated through the institution’s
clipsys cost accounting system, which captures hospital reimbursement as
ell as direct, variable, and fixed costs. Physician professional fees and
eimbursements were excluded. Data are presented as mean  standard
eviation.
Results: A total of 306 patients underwent CAS (n  132) or CEA
n 174). Hospital reimbursement was 18% higher for CAS ($12,000
5634) vs CEA ($10,160  $4687; P  .01). However, because of the
ignificantly higher materials’ costs of CAS, the net revenue (income) for
he hospital was 33% greater in patients undergoing CEA ($3426) than
AS ($2574) These differences in hospital reimbursement and net
Fig.ncome were consistent in asymptomatic (n  183), symptomatic (n 
23), and urgent (n  36) subgroups (see Fig). Asymptomatic patients
